Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

NTLA-2002

Gene editing · Gene editing: KLKB1 · developed by Intellia Therapeutics

Phase 3 Most advanced trial

NTLA Developer

2 Registered trials

What is NTLA-2002?

NTLA-2002 is a CRISPR/Cas9 gene editing system delivered by lipid nanoparticles for intravenous administration. It is being studied in hereditary angioedema.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Gene editing
Targets: KLKB1
Mechanism: Gene editing: KLKB1
Therapy area: Immunology
Developer: Intellia Therapeutics (NTLA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: D8UQ4B2T7M

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06634420	Phase 3	Hereditary Angioedema	Active not recruiting	NTLA
NCT05120830	Phase 1/2	Hereditary Angioedema	Active not recruiting	NTLA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hereditary Angioedema

Other drugs acting on KLKB1

Berotralstat FDA approved

More from Intellia Therapeutics

NTLA-2001 Phase 3 NTLA-3001 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the NTLA page.

Follow NTLA, the company behind NTLA-2002

See NTLA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NTLA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z